硼替佐米联合VAD方案治疗初治多发性骨髓瘤的临床观察  

Clinical Observation of Bortezomib Combined with VAD in the Treatment of Newly Diagnosed Multiple Myeloma

作　　者：孙园园[1] 潘静[1] 

机构地区：[1]辽宁医学院附属第一医院血液科,锦州市121000

出　　处：《中国药房》2011年第10期903-905,共3页China Pharmacy

摘　　要：目的:观察硼替佐米联合VAD方案治疗初治多发性骨髓瘤(MM)的初期疗效和安全性。方法:15例初治MM患者给予硼替佐米1.3mg.m-2,第1、4、8、11天静脉注射,每28天为1个疗程;每个疗程联合VAD方案化疗,每例患者至少接受2～8个疗程治疗。采用欧洲骨髓移植协作组(EBMT)标准评价其初步疗效,按美国国家癌症研究所不良事件常用名标准(NCI-CTCAE,version3.0)判断其毒副反应。结果:15例MM患者经过不同疗程的治疗,3例完全缓解,5例接近完全缓解,5例部分缓解,2例轻微缓解,总有效率达86.7%。最常见的毒副反应为胃肠道反应,有11例出现不同程度的胃肠道反应,其次为周围神经病变4例、乏力4例、肝功能损伤1例、带状疱疹1例,毒副反应分别经对症治疗后均获得一定程度的缓解。结论:硼替佐米联合VAD方案治疗初治MM疗效确切,患者可耐受。OBJECTIVE： To investigate the efficacy and safety of bortezomib combined with VAD in treatment of newly diagnosed multiple myeloma （MM）. METHODS： 15 newly diagnosed MM patients were given intravenous injection of 1.3 mg. m-2 bortezomib at 1 d, 4 d, 8 d, 11 d. Every treatment course lasted for 28 d. 15 patients were additionally given VAD regimen for 2 to 8 courses. Initial efficacy was evaluated according to the criteria of the European Group for Blood and Marrow Transplantation （EBMT）. Toxic reactions were graded according to the National Cancer Institute Common Terminology Criteria for Adverse Events, （NCI-CTCAE, version 3.0）. RESULTS： After giving different treatment courses, 3 cases obtained complete remission, 5 ca- serly nearly complete remission, 5 cases partial remission, 2 cases minimal remission. Clinical response rate of 15 patients was 86.7%. The most common adverse events were gastrointestinal symptoms （11 patients）, followed by peripheral neuropathy（4 patients）, fatigue （4 patients）, liver injury（1 patient） and herpes zoster （1 patient）. The adverse events were relieved by routine supportive care.CON- CLUSION： Bortezomib combined with VAD is accurately effective in the treatment of newly diagnosed MM and tolerable.

关 键 词：硼替佐米 VAD方案 初治多发性骨髓瘤 

分 类 号：R979.1[医药卫生—药品] R969.4[医药卫生—药学]